Cargando…
Longitudinal Assessment of Multimorbidity Medication Patterns among Smokers in the COPDGene Cohort
Background and objectives: Chronic obstructive pulmonary disease (COPD) is usually comorbid with other chronic diseases. We aimed to assess the multimorbidity medication patterns and explore if the patterns are similar for phase 1 (P1) and 5-year follow-up phase 2 (P2) in the COPDGene cohort. Materi...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10221198/ https://www.ncbi.nlm.nih.gov/pubmed/37241208 http://dx.doi.org/10.3390/medicina59050976 |
_version_ | 1785049398960455680 |
---|---|
author | Li, Yisha Schmiege, Sarah J. Anderson, Heather Richmond, Nicole E. Young, Kendra A. Hokanson, John E. Rennard, Stephen I. Crume, Tessa L. Austin, Erin Pratte, Katherine A. Conway, Rebecca Kinney, Gregory L. |
author_facet | Li, Yisha Schmiege, Sarah J. Anderson, Heather Richmond, Nicole E. Young, Kendra A. Hokanson, John E. Rennard, Stephen I. Crume, Tessa L. Austin, Erin Pratte, Katherine A. Conway, Rebecca Kinney, Gregory L. |
author_sort | Li, Yisha |
collection | PubMed |
description | Background and objectives: Chronic obstructive pulmonary disease (COPD) is usually comorbid with other chronic diseases. We aimed to assess the multimorbidity medication patterns and explore if the patterns are similar for phase 1 (P1) and 5-year follow-up phase 2 (P2) in the COPDGene cohort. Materials and Methods: A total of 5564 out of 10,198 smokers from the COPDGene cohort who completed 2 visits, P1 and P2 visits, with complete medication use history were included in the study. We conducted latent class analysis (LCA) among the 27 categories of chronic disease medications, excluding COPD treatments and cancer medications at P1 and P2 separately. The best number of LCA classes was determined through both statistical fit and interpretation of the patterns. Results: We found four classes of medication patterns at both phases. LCA showed that both phases shared similar characteristics in their medication patterns: LC0: low medication; LC1: hypertension (HTN) or cardiovascular disease (CVD)+high cholesterol (Hychol) medication predominant; LC2: HTN/CVD+type 2 diabetes (T2D) +Hychol medication predominant; LC3: Hychol medication predominant. Conclusions: We found similar multimorbidity medication patterns among smokers at P1 and P2 in the COPDGene cohort, which provides an understanding of how multimorbidity medication clustered and how different chronic diseases combine in smokers. |
format | Online Article Text |
id | pubmed-10221198 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102211982023-05-28 Longitudinal Assessment of Multimorbidity Medication Patterns among Smokers in the COPDGene Cohort Li, Yisha Schmiege, Sarah J. Anderson, Heather Richmond, Nicole E. Young, Kendra A. Hokanson, John E. Rennard, Stephen I. Crume, Tessa L. Austin, Erin Pratte, Katherine A. Conway, Rebecca Kinney, Gregory L. Medicina (Kaunas) Article Background and objectives: Chronic obstructive pulmonary disease (COPD) is usually comorbid with other chronic diseases. We aimed to assess the multimorbidity medication patterns and explore if the patterns are similar for phase 1 (P1) and 5-year follow-up phase 2 (P2) in the COPDGene cohort. Materials and Methods: A total of 5564 out of 10,198 smokers from the COPDGene cohort who completed 2 visits, P1 and P2 visits, with complete medication use history were included in the study. We conducted latent class analysis (LCA) among the 27 categories of chronic disease medications, excluding COPD treatments and cancer medications at P1 and P2 separately. The best number of LCA classes was determined through both statistical fit and interpretation of the patterns. Results: We found four classes of medication patterns at both phases. LCA showed that both phases shared similar characteristics in their medication patterns: LC0: low medication; LC1: hypertension (HTN) or cardiovascular disease (CVD)+high cholesterol (Hychol) medication predominant; LC2: HTN/CVD+type 2 diabetes (T2D) +Hychol medication predominant; LC3: Hychol medication predominant. Conclusions: We found similar multimorbidity medication patterns among smokers at P1 and P2 in the COPDGene cohort, which provides an understanding of how multimorbidity medication clustered and how different chronic diseases combine in smokers. MDPI 2023-05-18 /pmc/articles/PMC10221198/ /pubmed/37241208 http://dx.doi.org/10.3390/medicina59050976 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Li, Yisha Schmiege, Sarah J. Anderson, Heather Richmond, Nicole E. Young, Kendra A. Hokanson, John E. Rennard, Stephen I. Crume, Tessa L. Austin, Erin Pratte, Katherine A. Conway, Rebecca Kinney, Gregory L. Longitudinal Assessment of Multimorbidity Medication Patterns among Smokers in the COPDGene Cohort |
title | Longitudinal Assessment of Multimorbidity Medication Patterns among Smokers in the COPDGene Cohort |
title_full | Longitudinal Assessment of Multimorbidity Medication Patterns among Smokers in the COPDGene Cohort |
title_fullStr | Longitudinal Assessment of Multimorbidity Medication Patterns among Smokers in the COPDGene Cohort |
title_full_unstemmed | Longitudinal Assessment of Multimorbidity Medication Patterns among Smokers in the COPDGene Cohort |
title_short | Longitudinal Assessment of Multimorbidity Medication Patterns among Smokers in the COPDGene Cohort |
title_sort | longitudinal assessment of multimorbidity medication patterns among smokers in the copdgene cohort |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10221198/ https://www.ncbi.nlm.nih.gov/pubmed/37241208 http://dx.doi.org/10.3390/medicina59050976 |
work_keys_str_mv | AT liyisha longitudinalassessmentofmultimorbiditymedicationpatternsamongsmokersinthecopdgenecohort AT schmiegesarahj longitudinalassessmentofmultimorbiditymedicationpatternsamongsmokersinthecopdgenecohort AT andersonheather longitudinalassessmentofmultimorbiditymedicationpatternsamongsmokersinthecopdgenecohort AT richmondnicolee longitudinalassessmentofmultimorbiditymedicationpatternsamongsmokersinthecopdgenecohort AT youngkendraa longitudinalassessmentofmultimorbiditymedicationpatternsamongsmokersinthecopdgenecohort AT hokansonjohne longitudinalassessmentofmultimorbiditymedicationpatternsamongsmokersinthecopdgenecohort AT rennardstepheni longitudinalassessmentofmultimorbiditymedicationpatternsamongsmokersinthecopdgenecohort AT crumetessal longitudinalassessmentofmultimorbiditymedicationpatternsamongsmokersinthecopdgenecohort AT austinerin longitudinalassessmentofmultimorbiditymedicationpatternsamongsmokersinthecopdgenecohort AT prattekatherinea longitudinalassessmentofmultimorbiditymedicationpatternsamongsmokersinthecopdgenecohort AT conwayrebecca longitudinalassessmentofmultimorbiditymedicationpatternsamongsmokersinthecopdgenecohort AT kinneygregoryl longitudinalassessmentofmultimorbiditymedicationpatternsamongsmokersinthecopdgenecohort |